CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 target
Drug / intervention
cisplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00003945
NCT00003945Phase 3Completed
CompareCT.gov

A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix

Gynecologic Oncology Group·interventional·Posted Jan 27, 2003·Updated May 27, 2013

In Brief

A Phase 3 clinical trial evaluating cisplatin and topotecan hydrochloride for Cervical Cancer. Completed, enrolled 400 participants across 11 sites in 4 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for cervical cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of three different chemotherapy regimens in treating patients with stage IVB, recurrent, or persistent cervical cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesAustralia, Peru, Puerto Rico, United States
CollaboratorsNational Cancer Institute (NCI), Eastern Cooperative Oncology Group

Timeline

Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJun 1, 1999
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 23.4 years ago

Interventions

cisplatindrug

topotecan hydrochloridedrug